Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL

Nadeem Tabbara; Daria Gaut; Caspian Oliai; Tara Lewis; Sven de Vos

doi:10.1016/j.lrr.2021.100260

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL

Leuk Res Rep. 2021 Jul 14:16:100260. doi: 10.1016/j.lrr.2021.100260. eCollection 2021.

Authors

Nadeem Tabbara¹, Daria Gaut², Caspian Oliai², Tara Lewis², Sven de Vos²

Affiliations

¹ Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 2020 Santa Monica Blvd, Suite 600, Los Angeles, CA 90404, USA.
² Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Abstract

Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (LEN), reported progression-free survival of 16 months in R/R DLBCL patients ineligible for autologous stem cell transplantation. Despite recent advances in anti-CD19 therapy, no clinical evidence exists to direct the sequencing of CAR T cell therapy following relapse after prior anti-CD19 therapy. We present the first published case of TAFA/LEN treatment followed by CAR T therapy with sustained remission. Disease progression following treatment with Tafasitamab may not preclude patients from CAR T cell therapy.

Keywords: CD19; Chimeric antigen receptor T-cell therapy; Diffuse large B-cell lymphoma; Tafasitamab.

Publication types

Case Reports